AXNX News and Press, Axonics Modulation Technologies Inc. From 06/13/21

Inflation is here; and that means these groups ought to be on your radar. The best stocks within every sector now. Over 20 new stocks join our 'best stocks' list this week. For further details see: The Stocks To Focus On Today

Axonics (AXNX) has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI scans. The FDA previously approved 1.5T and 3.0T MRI conditional labeling for using head and full-body transmit coils for the implantable components of the Axonics...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI ...

Axonics (AXNX) announces European CE Mark approval of its second generation Axonics r-SNM implantable neurostimulator ((INS)) and wireless patient remote control with SmartMRI technology. Axonics previously received FDA approval for this INS and remote control during 2020. This version r...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced European CE Mark approval of its second generation Axonics r-SNM ® implantable neurostimul...

Axonics (AXNX) has priced its public offering of 3.5M common shares at $50.00/share, for expected gross proceeds of $175M.Underwriters' over-allotment is an additional 525K shares. Net proceeds will be used to repay outstanding indebtedness, for commercialization purpose, R&D activities, ...

Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 3,500,000 shares of its common s...

Axonics (AXNX) announces that it has commenced a proposed public offering of $150M in shares.Expects to grant the underwriters a 30-day option to purchase up to $22.5M in additional shares.Axonics anticipates using net proceeds to repay all or a portion of its outstanding indebtedness of $75M...

Axonics, Inc. (AXNX) Q1 2021 Earnings Conference Call May 06, 2021 4:30 PM ET Company Participants Neil Bhalodkar – Investor Relations Raymond Cohen – Chief Executive Officer Dan Dearen – President and Chief Financial Officer Conference Call Participants Bob Hopkins ...

Axonics Modulation Technologies (AXNX): Q1 GAAP EPS of -$0.57 misses by $0.17.Revenue of $34.4M (+30.8% Y/Y) beats by $6.47M.Axonics anticipates fiscal year 2021 net revenue to be in the range of $176 million to $180 million vs. consensus of $169.90M, which would represent growth of approxima...